144 related articles for article (PubMed ID: 9616151)
21. Tyrosine phosphorylation regulates the SH3-mediated binding of the Wiskott-Aldrich syndrome protein to PSTPIP, a cytoskeletal-associated protein.
Wu Y; Spencer SD; Lasky LA
J Biol Chem; 1998 Mar; 273(10):5765-70. PubMed ID: 9488710
[TBL] [Abstract][Full Text] [Related]
22. Wiskott-Aldrich syndrome protein and platelets.
Oda A; Ochs HD
Immunol Rev; 2000 Dec; 178():111-7. PubMed ID: 11213795
[TBL] [Abstract][Full Text] [Related]
23. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia.
Devriendt K; Kim AS; Mathijs G; Frints SG; Schwartz M; Van Den Oord JJ; Verhoef GE; Boogaerts MA; Fryns JP; You D; Rosen MK; Vandenberghe P
Nat Genet; 2001 Mar; 27(3):313-7. PubMed ID: 11242115
[TBL] [Abstract][Full Text] [Related]
24. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice.
Klein C; Nguyen D; Liu CH; Mizoguchi A; Bhan AK; Miki H; Takenawa T; Rosen FS; Alt FW; Mulligan RC; Snapper SB
Blood; 2003 Mar; 101(6):2159-66. PubMed ID: 12433691
[TBL] [Abstract][Full Text] [Related]
25. Two novel mutations of Wiskott-Aldrich syndrome: the molecular prediction of interaction between the mutated WASP L101P with WASP-interacting protein by molecular modeling.
Kim MK; Kim ES; Kim DS; Choi IH; Moon T; Yoon CN; Shin JS
Biochim Biophys Acta; 2004 Oct; 1690(2):134-40. PubMed ID: 15469902
[TBL] [Abstract][Full Text] [Related]
26. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
27. Studies of the expression of the Wiskott-Aldrich syndrome protein.
Stewart DM; Treiber-Held S; Kurman CC; Facchetti F; Notarangelo LD; Nelson DL
J Clin Invest; 1996 Jun; 97(11):2627-34. PubMed ID: 8647957
[TBL] [Abstract][Full Text] [Related]
28. WASP gene mutations in Wiskott-Aldrich syndrome and X-linked thrombocytopenia.
Derry JM; Kerns JA; Weinberg KI; Ochs HD; Volpini V; Estivill X; Walker AP; Francke U
Hum Mol Genet; 1995 Jul; 4(7):1127-35. PubMed ID: 8528199
[TBL] [Abstract][Full Text] [Related]
29. Disruption of hSWI/SNF complexes in T cells by WAS mutations distinguishes X-linked thrombocytopenia from Wiskott-Aldrich syndrome.
Sarkar K; Sadhukhan S; Han SS; Vyas YM
Blood; 2014 Nov; 124(23):3409-19. PubMed ID: 25253772
[TBL] [Abstract][Full Text] [Related]
30. Novel mutations in the Wiskott-Aldrich syndrome protein gene and their effects on transcriptional, translational, and clinical phenotypes.
Lemahieu V; Gastier JM; Francke U
Hum Mutat; 1999; 14(1):54-66. PubMed ID: 10447259
[TBL] [Abstract][Full Text] [Related]
31. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
Boztug K; Dewey RA; Klein C
Curr Opin Mol Ther; 2006 Oct; 8(5):390-5. PubMed ID: 17078381
[TBL] [Abstract][Full Text] [Related]
32. [Molecular pathogenesis of Wiskott-Aldrich syndrome].
Sasahara Y; Tsuchiya S
Nihon Rinsho Meneki Gakkai Kaishi; 2005 Jun; 28(3):140-7. PubMed ID: 15997177
[TBL] [Abstract][Full Text] [Related]
33. Wiskott-Aldrich syndrome.
Notarangelo LD; Miao CH; Ochs HD
Curr Opin Hematol; 2008 Jan; 15(1):30-6. PubMed ID: 18043243
[TBL] [Abstract][Full Text] [Related]
34. The Wiskott-Aldrich syndrome protein (WASP): roles in signaling and cytoskeletal organization.
Snapper SB; Rosen FS
Annu Rev Immunol; 1999; 17():905-29. PubMed ID: 10358777
[TBL] [Abstract][Full Text] [Related]
35. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome.
Astrakhan A; Sather BD; Ryu BY; Khim S; Singh S; Humblet-Baron S; Ochs HD; Miao CH; Rawlings DJ
Blood; 2012 May; 119(19):4395-407. PubMed ID: 22431569
[TBL] [Abstract][Full Text] [Related]
36. Mutational analysis of the WASP gene in 2 Korean families with Wiskott-Aldrich syndrome.
Jo EK; Futatani T; Kanegane H; Kubota T; Lee YH; Jung JA; Song CH; Park JK; Nonoyama S; Miyawaki T
Int J Hematol; 2003 Jul; 78(1):40-4. PubMed ID: 12894849
[TBL] [Abstract][Full Text] [Related]
37. Mutations that cause the Wiskott-Aldrich syndrome impair the interaction of Wiskott-Aldrich syndrome protein (WASP) with WASP interacting protein.
Stewart DM; Tian L; Nelson DL
J Immunol; 1999 Apr; 162(8):5019-24. PubMed ID: 10202051
[TBL] [Abstract][Full Text] [Related]
38. The pleckstrin homology domain of the Wiskott-Aldrich syndrome protein is involved in the organization of actin cytoskeleton.
Imai K; Nonoyama S; Miki H; Morio T; Fukami K; Zhu Q; Aruffo A; Ochs HD; Yata J; Takenawa T
Clin Immunol; 1999 Aug; 92(2):128-37. PubMed ID: 10444357
[TBL] [Abstract][Full Text] [Related]
39. The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene.
Zhu Q; Zhang M; Blaese RM; Derry JM; Junker A; Francke U; Chen SH; Ochs HD
Blood; 1995 Nov; 86(10):3797-804. PubMed ID: 7579347
[TBL] [Abstract][Full Text] [Related]
40. Wiskott-Aldrich Syndrome causing mutation, Pro373Ser restricts conformational changes essential for WASP activity in T-cells.
Jain N; George B; Thanabalu T
Biochim Biophys Acta; 2014 Apr; 1842(4):623-34. PubMed ID: 24440360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
